A Novel bispecific T-cell engager (BiTE) targeting CD22 and CD3 has both in vitro and in vivo activity and synergizes with blinatumomab in an acute lymphoblastic leukemia (ALL) tumor model

Immunotherapy has revolutionized cancer therapy. Two recently FDA-approved immunotherapies for B-cell malignancies target CD19, in the form of a Bispecific T-Cell Engager (BiTE) antibody construct or chimeric antigen receptor T (CAR-T) cells. Blinatumomab, an FDA-approved BiTE, binds to CD19 on B ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Meckler, Joshua F., Levis, Daniel J., Vang, Daniel P., Tuscano, Joseph M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10412491/
https://www.ncbi.nlm.nih.gov/pubmed/37247022
http://dx.doi.org/10.1007/s00262-023-03444-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10412491/
https://www.ncbi.nlm.nih.gov/pubmed/37247022
http://dx.doi.org/10.1007/s00262-023-03444-0

Ejemplares similares